My interest in history in general evolved from the interest
in medicine in particular that began right after my residency training. Recently I have been reading about the
developments of liver transplant and monoclonal antibody. Speaking of liver transplant, one cannot escape
the story of cyclosporine.
In a 7/30/1981 New
York Times report showing a stunning success of liver transplant, using
cyclosporine (or cyclosporine A) to overcome the rejection of the transplant
organ. This report was based on a New England Journal of Medicine article
of the same date.
In the NEJM article
as well as NY Times article, Dr.
Thomas Starzl reported 10 of the 12 persons survived one year after surgery or
83% (two died on the operating table).
The survival rate was 32% among the 170 liver transplants that he
performed over the 17 years period before using cyclosporine.
Dr. Starzl performed the first liver transplant in a
3-year-old boy with biliary atresia in 1963; the boy bled to death on table. He did five more cases of liver transplants
in 1964; all died of hemorrhage or infection within 23 days of transplants. This was followed by four years of
moratorium. Dr. Starzl began to use
cyclosporine at University of Colorado before he moved to University of
Pittsburgh January 1981.
The success of cyclosporine lies in the fact that it
suppresses the body’s natural immunity so that it will not attack the
transplant organ and yet it doesn’t hamper the body’s ability to fight off
infections.
Cyclosporine was first used in 22 kidney transplants
(survival rate of 85%) before it was used in liver transplant. Dr. Roy Calne of Cambridge University was the
first to use cyclosporine in liver transplant.
The development of cyclosporine was not all rosy and smooth, at one time
Sandoz threatened to discontinue the project because of the toxicity to kidney. Dr. Calne flew to
Basel [where Sandoz based] and successfully appealed the decision, allowing an
experimental supply to continue. Dr. Starzl
and Dr. Calne shared the 2012 Lasker Award.
Speaking of cyclosporine, it would
be remiss of me not to mention Dr. Chao-Long Chen (陳肇隆醫師院士), the father of liver
transplant in Asia/Taiwan. After
completing the liver transplant training with Dr. Starzl in 1983, he returned
to Taiwan, at which time cyclosporine, not yet approved by FDA, was still an
experimental drug.
Realizing there cannot be a
success of liver transplant without cyclosporine, Dr. Chen, armed with a
recommendation letter from Dr. Starzl, flew to Basel, Switzerland (where Sandoz
is based) to apply for the use of the then experimental cyclosporine and was
granted for the supply for five patients.
Dr. Chen had a photo taken with
Dr. Borel then and again had a photo taken with him in October 2016, 33 years and
more than 1,500 liver transplants later, when Dr. Chen was invited to give a
talk at the prestigious 15th Borel-Stӓhelin Lecture, named in honor of Dr. Jean Borel. Dr. Chen was the first non-European/American
doctor to be granted for this honor.
In the late 1960s Sandoz
discovered two strains of fungi in soil samples. The fungi produced substance that they hope
can be developed into antibiotic. It was a fateful twist that Professor Jean Borel of Sandoz who discovered the substance can suppress body’s
immune system in 1970-73 and eventually cyclosporine came into being.
Dr. Chen’s lecture at University
Hospital Zurich on October 11, 2016 was “Perspectives on Liver Transplantation,
Innovation, Education and Beyond”
(I gave a talk of liver transplant to the Taiwanese American community, this is the Power Point)
Dr. Starzl spoke at Dr. Borel’s retirement banquet in 1999;
this is how Dr. Starzl began,
“THANK YOU, ladies and gentlemen,
and especially Jean Borel. I am honored to be here, and especially by the
chance to speak. More than a retirement banquet, we celebrate tonight and
tomorrow the descent of a hero from Mt. Olympus. How you, Jean Borel, managed
to scale such heights, and returned unscathed is a question to which I will
return in a moment. But first, I want to say something about what your journey
meant to me personally, and eventually to everyone else in this room, and in
the world.”
After talking about the dismal
outcome of liver transplants of 17 years prior to the era of cyclosporine came around, Dr. Starzl said,
“At the darkest and most
unexpected moment, a mounted torch-bearer appeared in the distance. The torch
was cyclosporine; the bearer was Jean Borel, and the horse was the Sandoz
Corporation. How the next steps were taken by Roy Caine and his English
colleagues is the material of legends. Suffice it to say, both the patients and
those who cared for them were liberated from a terrible bondage. There have
been improvements in treatment since then, and there will be more. None, in my
opinion, will compare in magnitude to those that occurred between 1978 and 1980
as the result of Jean Borel's initiative.”
Professor Borel’s first love was art and
that “allowed him to exercise the imagination and creativity of the
artist in the pursuit of science. The result was vision.”
Dr. Starzl closed his remark very
appropriately at a retirement banquet,
“As for Jean Borel, don't count
him out. There are pictures to be
painted, music to be composed, and words to be written. And there is still plenty of time.”
Cyclosporine brought the liver transplants out of dark age. Dr. Thomas Starzl felt he owed his
career to Professor Borel’s ingenious and creative work on cyclosporine; this feeling,
I think, must be shared by Dr. Chao-Long Chen.